BUZZ-Tevogen rises as AI platform upgrade boosts drug discovery push

Reuters03-14

** Shares of biotech firm Tevogen Bio TVGN.O rise as much as 7.9% to $6.87 in afternoon trading

** Co says its Tevogen.AI platform improved accuracy in predicting drug targets most likely to work in patients, helping cut trial-and-error in drug development

** Platform now analyzes more than 655 mln peptide sequences from about 24 mln proteins, drawing on data from 37 mln scientific papers, co says

** TVGN adds its PredicTcell model lifted recall to 92% from 87% and precision to 48% from 40% in recent tests

** Says it is seeking partnerships with drugmakers to advance select peptide candidates across cancer, virus and brain disease programs

** Shares down ~68% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2619111673?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-14 00:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619111673","market":"us","top_or_hot":-1,"title":"BUZZ-Tevogen rises as AI platform upgrade boosts drug discovery push","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Tevogen rises as AI platform upgrade boosts drug discovery push</title></head><body><p>** Shares of biotech firm <a href=\"https://laohu8.com/S/TVGN\">Tevogen Bio</a> <span>TVGN.O</span> rise as much as 7.9% to $6.87 in afternoon trading </p><p>** Co says its Tevogen.AI platform improved accuracy in predicting drug targets most likely to work in patients, helping cut trial-and-error in drug development</p><p>** Platform now analyzes more than 655 mln peptide sequences from about 24 mln proteins, drawing on data from 37 mln scientific papers, co says</p><p>** TVGN adds its PredicTcell model lifted recall to 92% from 87% and precision to 48% from 40% in recent tests</p><p>** Says it is seeking partnerships with drugmakers to advance select peptide candidates across cancer, virus and brain disease programs</p><p>** Shares down ~68% in 2025</p><p>(Reporting by Sahil Pandey in Bengaluru)</p><p>((Sahil.Pandey@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Tevogen rises as AI platform upgrade boosts drug discovery push</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Tevogen rises as AI platform upgrade boosts drug discovery push\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-14 00:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Tevogen rises as AI platform upgrade boosts drug discovery push</title></head><body><p>** Shares of biotech firm <a href=\"https://laohu8.com/S/TVGN\">Tevogen Bio</a> <span>TVGN.O</span> rise as much as 7.9% to $6.87 in afternoon trading </p><p>** Co says its Tevogen.AI platform improved accuracy in predicting drug targets most likely to work in patients, helping cut trial-and-error in drug development</p><p>** Platform now analyzes more than 655 mln peptide sequences from about 24 mln proteins, drawing on data from 37 mln scientific papers, co says</p><p>** TVGN adds its PredicTcell model lifted recall to 92% from 87% and precision to 48% from 40% in recent tests</p><p>** Says it is seeking partnerships with drugmakers to advance select peptide candidates across cancer, virus and brain disease programs</p><p>** Shares down ~68% in 2025</p><p>(Reporting by Sahil Pandey in Bengaluru)</p><p>((Sahil.Pandey@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nL4N4011F7:1","article_id":"2619111673","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2619111673","pubTimestamp":1773420216,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Tevogen rises as AI platform upgrade boosts drug discovery push** Shares of biotech firm Tevogen Bio TVGN.O rise as much as 7.9% to $6.87 in afternoon trading ** Co says its Tevogen.AI platform improved accuracy in predicting drug targets most likely to work in patients, helping cut trial-and-error in drug development** Platform now analyzes more than 655 mln peptide sequences from about 24 mln proteins, drawing on data from 37 mln scientific papers, co says** TVGN adds its PredicTcell model lifted recall to 92% from 87% and precision to 48% from 40% in recent tests** Says it is seeking partnerships with drugmakers to advance select peptide candidates across cancer, virus and brain disease programs** Shares down ~68% in 2025","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","TVGN":"Tevogen Bio Holdings"},"translate_title":"BUZZ-Tevogen崛起，人工智能平台升级推动药物发现","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TVGN":0.9},"content_text":"BUZZ-Tevogen rises as AI platform upgrade boosts drug discovery push** Shares of biotech firm Tevogen Bio TVGN.O rise as much as 7.9% to $6.87 in afternoon trading ** Co says its Tevogen.AI platform improved accuracy in predicting drug targets most likely to work in patients, helping cut trial-and-error in drug development** Platform now analyzes more than 655 mln peptide sequences from about 24 mln proteins, drawing on data from 37 mln scientific papers, co says** TVGN adds its PredicTcell model lifted recall to 92% from 87% and precision to 48% from 40% in recent tests** Says it is seeking partnerships with drugmakers to advance select peptide candidates across cancer, virus and brain disease programs** Shares down ~68% in 2025(Reporting by Sahil Pandey in Bengaluru)((Sahil.Pandey@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2619111673","isCrawlerRequest":true}